このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

An Evaluation of the Potential for VH4011499 Drug-drug-interactions

2026年11月9日 更新者:ViiV Healthcare

A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants

The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.

調査の概要

状態

まだ募集していません

条件

介入・治療

研究の種類

介入

入学 (推定)

75

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~60年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form (ICF).

  • Male or female:

    1. Male Participants:

      No restrictions for male participants.

    2. A female participant (female sex assigned at birth) is eligible to participate if:

They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of contraception since, to be eligible, they must be of nonchildbearing potential.

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
  • Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
  • Capable of giving signed informed consent.

Exclusion Criteria:

  • History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
  • Pre-existing clinically relevant, gastro-intestinal pathology or diagnosis.
  • A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
  • Clinically significant abnormal blood pressure at Screening.
  • Lymphoma, leukemia, or any malignancy within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
  • Breast cancer within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
  • History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long QT syndrome.
  • History of seizure(s) and / or other clinically significant neurological conditions.
  • Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
  • Participants with any history of any drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
  • Participant is mentally or legally incapacitated.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
  • Unable to refrain from the use of prescription or non-prescription medications.
  • Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
  • Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
  • Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
  • Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
  • Current enrollment or past participation in this clinical study.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • eGFR <90 mL/min or serum creatinine >1.1× upper limit of normal (ULN) .
  • Hemoglobin <12.5 g/dL for men and <11 g/dL for women.
  • Participants with active hepatitis B virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
  • Positive Hepatitis C antibody test result at Screening.
  • Positive pre-study drug/alcohol screen.
  • Positive HIV-1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium <135 millimole/L.
  • Regular alcohol consumption within 6 months prior to Screening.
  • Regular use of known drugs of abuse.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
  • Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
  • Prior exposure to VH4011499 or Lenacapavir in any formulation..
  • Study participants with ALT >1.0x ULN or total bilirubin >1.5x ULN are excluded at Screening.
  • Any significant arrhythmia or ECG findings meeting protocol-defined exclusion criteria.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 1: VH4011499 + Ritonavir

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir.

VH4011499 is administered to the participants based on the protocol schedule.

Ritonavir is administered to the participants based on the protocol schedule.

実験的:Cohort 2: VH4011499 + Efavirenz

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz.

VH4011499 is administered to the participants based on the protocol schedule.

Efavirenz is administered to the participants based on the protocol schedule.

実験的:Cohort 3: VH4011499 + Carbamazepine

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose.

VH4011499 is administered to the participants based on the protocol schedule.

Carbamazepine is administered to the participants based on the protocol schedule.

実験的:Cohort 4: VH4011499 + Metformin + Digoxin

Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Metformin is administered to the participants based on the protocol schedule.

Digoxin is administered to the participants based on the protocol schedule.

実験的:Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin

Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Rosuvastatin is administered to the participants based on the protocol schedule.

Pitavastatin is administered to the participants based on the protocol schedule.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
時間枠:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Cmax of VH4011499 when co-administered with Ritonavir
時間枠:Day 26
Day 26
Cmax of VH4011499 when co-administered with Efavirenz
時間枠:Day 37
Day 37
Cmax of VH4011499 when co-administered with Carbamazepine
時間枠:Day 41
Day 41
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
時間枠:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-t) of VH4011499 when co-administered with Ritonavir
時間枠:Day 26
Day 26
AUC(0-t) of VH4011499 when co-administered with Efavirenz
時間枠:Day 37
Day 37
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
時間枠:Day 41
Day 41
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
時間枠:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
時間枠:Day 26
Day 26
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
時間枠:Day 37
Day 37
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
時間枠:Day 41
Day 41
Cmax of Metformin when administered alone
時間枠:Day 1
Day 1
Cmax of Metformin when co-administered with VH4011499
時間枠:Day 16
Day 16
AUC(0-t) of Metformin when administered alone
時間枠:Day 1
Day 1
AUC(0-t) of Metformin when co-administered with VH4011499
時間枠:Day 16
Day 16
AUC(0-inf) of Metformin when administered alone
時間枠:Day 1
Day 1
AUC(0-inf) of Metformin when co-administered with VH4011499
時間枠:Day 16
Day 16
Cmax of Digoxin when administered alone
時間枠:Day 1
Day 1
Cmax of Digoxin when co-administered with VH4011499
時間枠:Day 16
Day 16
AUC(0-t) of Digoxin when administered alone
時間枠:Day 1
Day 1
AUC(0-t) of Digoxin when co-administered with VH4011499
時間枠:Day 16
Day 16
AUC(0-inf) of Digoxin when administered alone
時間枠:Day 1
Day 1
AUC(0-inf) of Digoxin when co-administered with VH4011499
時間枠:Day 16
Day 16
Cmax of Rosuvastatin when administered alone
時間枠:Day 5
Day 5
Cmax of Rosuvastatin when co-administered with VH4011499
時間枠:Day 22
Day 22
AUC(0-t) of Rosuvastatin when administered alone
時間枠:Day 5
Day 5
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
時間枠:Day 22
Day 22
AUC(0-inf) of Rosuvastatin when administered alone
時間枠:Day 5
Day 5
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
時間枠:Day 22
Day 22
Cmax of Pitavastatin when administered alone
時間枠:Day 1
Day 1
Cmax of Pitavastatin when co-administered with VH4011499
時間枠:Day 17
Day 17
AUC(0-t) of Pitavastatin when administered alone
時間枠:Day 1
Day 1
AUC(0-t) of Pitavastatin when co-administered with VH4011499
時間枠:Day 17
Day 17
AUC(0-inf) of Pitavastatin when administered alone
時間枠:Day 1
Day 1
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
時間枠:Day 17
Day 17

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of participants with adverse events (AEs), overall and by grade.
時間枠:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with AEs leading to study treatment discontinuation
時間枠:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
時間枠:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
時間枠:Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
時間枠:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Tmax of VH4011499 when co-administered with Ritonavir
時間枠:Day 26
Day 26
Tmax of VH4011499 when co-administered with Efavirenz
時間枠:Day 37
Day 37
Tmax of VH4011499 when co-administered with Carbamazepine
時間枠:Day 41
Day 41
Apparent oral clearance (CL/F) of VH4011499 when administered alone
時間枠:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
CL/F of VH4011499 when co-administered with Ritonavir
時間枠:Day 26
Day 26
CL/F of VH4011499 when co-administered with Efavirenz
時間枠:Day 37
Day 37
CL/F of VH4011499 when co-administered with Carbamazepine
時間枠:Day 41
Day 41
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
時間枠:Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
t1/2 of VH4011499 when co-administered with Ritonavir
時間枠:Day 26
Day 26
t1/2 of VH4011499 when co-administered with Efavirenz
時間枠:Day 37
Day 37
t1/2 of VH4011499 when co-administered with Carbamazepine
時間枠:Day 41
Day 41
Cmax of VH4011499 when co-administered with Metformin and Digoxin
時間枠:Day 16
Day 16
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
時間枠:Day 16
Day 16
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
時間枠:Day 16
Day 16
Cmax of Ritonavir when co-administered with VH4011499
時間枠:Day 26
Day 26
AUC(0-t) of Ritonavir when co-administered with VH4011499
時間枠:Day 26
Day 26
AUC(0-inf) of Ritonavir when co-administered with VH4011499
時間枠:Day 26
Day 26
Cmax of Efavirenz when co-administered with VH4011499
時間枠:Day 37
Day 37
AUC(0-t) of Efavirenz when co-administered with VH4011499
時間枠:Day 37
Day 37
AUC(0-inf) of Efavirenz when co-administered with VH4011499
時間枠:Day 37
Day 37
Cmax of Carbamazepine when co-administered with VH4011499
時間枠:Day 41
Day 41
AUC(0-t) of Carbamazepine when co-administered with VH4011499
時間枠:Day 41
Day 41
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
時間枠:Day 41
Day 41
Cmax of VH4011499 when co-administered with Rosuvastatin
時間枠:Day 22
Day 22
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
時間枠:Day 22
Day 22
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
時間枠:Day 22
Day 22
Cmax of VH4011499 when co-administered with Pitavastatin
時間枠:Day 17
Day 17
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
時間枠:Day 17
Day 17
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
時間枠:Day 17
Day 17

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月16日

一次修了 (推定)

2027年3月12日

研究の完了 (推定)

2027年3月12日

試験登録日

最初に提出

2026年11月9日

QC基準を満たした最初の提出物

2026年11月9日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 309014

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

IPD 共有時間枠

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD 共有アクセス基準

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。